G Villafane1, C Thiriez1,2, E Audureau3,4, C Straczek5,6, P Kerschen1, F Cormier-Dequaire7,8, A Van Der Gucht9,10, J-M Gurruchaga11,12, M Quéré-Carne5, E Evangelista9, M Paul6, G Defer13,14, P Damier15, P Remy1,2,16, E Itti9,10, G Fénelon1,2,17,18. 1. Department of Neurology, APHP, CHU Henri Mondor, Créteil, France. 2. Centre Expert Parkinson Henri Mondor, Créteil, France. 3. Department of Public Health, APHP, CHU Henri Mondor, Créteil, France. 4. CEpiA EA7376, UPEC, Créteil, France. 5. Clinical Research Unit, APHP, CHU Henri Mondor, Créteil, France. 6. Pharmacy Department, CHU Henri Mondor, Créteil, France. 7. APHP, CHU Pitié Salpétrière, Paris, France. 8. UPMC, Paris, France. 9. Department of Nuclear Medicine, APHP, CHU Henri Mondor, Créteil, France. 10. UPEC, Créteil, France. 11. Department of Neurosurgery, APHP, CHU Henri Mondor, Créteil, France. 12. Equipe 14, Inserm U955, Créteil, France. 13. Neurology, CHU Caen, Caen, France. 14. INSERM U919 GIP Cyceron, Normandie Université, Caen, France. 15. CIC 004, CHU Nantes, INSERM, Nantes, France. 16. MIRCen, CEA/DSV and NeuRATRIS, Fontenay-aux-Roses, France. 17. Département d'Etudes Cognitives, Ecole Normale Supérieure, PSL Research University, Paris, France. 18. Inserm U955, Equipe E01 Neuropsychologie Interventionnelle, Créteil, France.
Abstract
BACKGROUND AND PURPOSE: Studies of the effects of nicotine on motor symptoms in Parkinson's disease (PD) brought out discordant results. The aim of the present study was to evaluate the efficacy and safety of high doses of transdermal nicotine on motor symptoms in PD. METHODS:Forty PD patients were randomly assigned to a treated and untreated arm in an open-label study. Treated patients received increasing doses of nicotine to reach 90 mg/day by 11 weeks. This dosage was maintained for 28 weeks (W39) and then reduced over 6 weeks. Final evaluation was performed 6 weeks after washout. The main outcome measure was the OFF-DOPA Unified Parkinson's Disease Rating Scale (UPDRS) motor score measured on video recordings by raters blinded to the medication status of the patients. RESULTS: There was no significant difference in OFF-DOPA UPDRS motor scores between the nicotine-treated and non-treated groups, neither at W39 (19.4 ± 9.3 vs. 21.5 ± 14.2) nor considering W39 differences from baseline (-1.5 ± 12.1 vs. +0.9 ± 12.1). The 39-item Parkinson's disease questionnaire scores decreased in nicotine-treated patients and increased in non-treated patients, but the difference was not significant. Overall tolerability was acceptable, and 12/20 treated patients reached the maximal dosage. CONCLUSIONS: High doses of transdermal nicotine were tolerated, but our study failed to demonstrate significant improvement in UPDRS motor scores. Improvement in unblinded secondary outcomes (UPDRS-II, UPDRS-IV, doses of l-DOPA equivalents) suggest a possible benefit for patients treated with nicotine, which should be confirmed in larger double blind, placebo-controlled studies.
RCT Entities:
BACKGROUND AND PURPOSE: Studies of the effects of nicotine on motor symptoms in Parkinson's disease (PD) brought out discordant results. The aim of the present study was to evaluate the efficacy and safety of high doses of transdermal nicotine on motor symptoms in PD. METHODS: Forty PDpatients were randomly assigned to a treated and untreated arm in an open-label study. Treated patients received increasing doses of nicotine to reach 90 mg/day by 11 weeks. This dosage was maintained for 28 weeks (W39) and then reduced over 6 weeks. Final evaluation was performed 6 weeks after washout. The main outcome measure was the OFF-DOPA Unified Parkinson's Disease Rating Scale (UPDRS) motor score measured on video recordings by raters blinded to the medication status of the patients. RESULTS: There was no significant difference in OFF-DOPA UPDRS motor scores between the nicotine-treated and non-treated groups, neither at W39 (19.4 ± 9.3 vs. 21.5 ± 14.2) nor considering W39 differences from baseline (-1.5 ± 12.1 vs. +0.9 ± 12.1). The 39-item Parkinson's disease questionnaire scores decreased in nicotine-treated patients and increased in non-treated patients, but the difference was not significant. Overall tolerability was acceptable, and 12/20 treated patients reached the maximal dosage. CONCLUSIONS: High doses of transdermal nicotine were tolerated, but our study failed to demonstrate significant improvement in UPDRS motor scores. Improvement in unblinded secondary outcomes (UPDRS-II, UPDRS-IV, doses of l-DOPA equivalents) suggest a possible benefit for patients treated with nicotine, which should be confirmed in larger double blind, placebo-controlled studies.
Authors: Cloé Domenighetti; Pierre-Emmanuel Sugier; Ashwin Ashok Kumar Sreelatha; Claudia Schulte; Sandeep Grover; Océane Mohamed; Berta Portugal; Patrick May; Dheeraj R Bobbili; Milena Radivojkov-Blagojevic; Peter Lichtner; Andrew B Singleton; Dena G Hernandez; Connor Edsall; George D Mellick; Alexander Zimprich; Walter Pirker; Ekaterina Rogaeva; Anthony E Lang; Sulev Koks; Pille Taba; Suzanne Lesage; Alexis Brice; Jean-Christophe Corvol; Marie-Christine Chartier-Harlin; Eugénie Mutez; Kathrin Brockmann; Angela B Deutschländer; Georges M Hadjigeorgiou; Efthimos Dardiotis; Leonidas Stefanis; Athina Maria Simitsi; Enza Maria Valente; Simona Petrucci; Stefano Duga; Letizia Straniero; Anna Zecchinelli; Gianni Pezzoli; Laura Brighina; Carlo Ferrarese; Grazia Annesi; Andrea Quattrone; Monica Gagliardi; Hirotaka Matsuo; Yusuke Kawamura; Nobutaka Hattori; Kenya Nishioka; Sun Ju Chung; Yun Joong Kim; Pierre Kolber; Bart Pc van de Warrenburg; Bastiaan R Bloem; Jan Aasly; Mathias Toft; Lasse Pihlstrøm; Leonor Correia Guedes; Joaquim J Ferreira; Soraya Bardien; Jonathan Carr; Eduardo Tolosa; Mario Ezquerra; Pau Pastor; Monica Diez-Fairen; Karin Wirdefeldt; Nancy L Pedersen; Caroline Ran; Andrea C Belin; Andreas Puschmann; Clara Hellberg; Carl E Clarke; Karen E Morrison; Manuela Tan; Dimitri Krainc; Lena F Burbulla; Matt J Farrer; Rejko Krüger; Thomas Gasser; Manu Sharma; Alexis Elbaz Journal: J Parkinsons Dis Date: 2022 Impact factor: 5.520
Authors: Sara M Zarate; Gauri Pandey; Sunanda Chilukuri; Jose A Garcia; Brittany Cude; Shannon Storey; Nihal A Salem; Eric A Bancroft; Michelle Hook; Rahul Srinivasan Journal: J Neurochem Date: 2021-01-10 Impact factor: 5.372
Authors: N Vila-Chã; S Cavaco; A Mendes; A Gonçalves; I Moreira; J Fernandes; J Damásio; L F Azevedo; J M Castro-Lopes Journal: Parkinsons Dis Date: 2021-06-10